- Home
- RIGL vs BRDG Comparison
RIGL vs BRDG Comparison
Compare RIGL & BRDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BRDG
- Stock Information
- Founded
- RIGL 1996
- BRDG 2009
- Country
- RIGL United States
- BRDG United States
- Employees
- RIGL N/A
- BRDG N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BRDG Investment Managers
- Sector
- RIGL Health Care
- BRDG Finance
- Exchange
- RIGL Nasdaq
- BRDG Nasdaq
- Market Cap
- RIGL 335.5M
- BRDG 391.6M
- IPO Year
- RIGL 2000
- BRDG 2021
- Fundamental
- Price
- RIGL $20.97
- BRDG $9.18
- Analyst Decision
- RIGL Buy
- BRDG Hold
- Analyst Count
- RIGL 5
- BRDG 5
- Target Price
- RIGL $36.40
- BRDG $11.30
- AVG Volume (30 Days)
- RIGL 217.1K
- BRDG 315.3K
- Earning Date
- RIGL 08-05-2025
- BRDG 06-10-2025
- Dividend Yield
- RIGL N/A
- BRDG 4.98%
- EPS Growth
- RIGL N/A
- BRDG N/A
- EPS
- RIGL 2.08
- BRDG N/A
- Revenue
- RIGL $203,077,000.00
- BRDG $453,729,000.00
- Revenue This Year
- RIGL $14.41
- BRDG N/A
- Revenue Next Year
- RIGL $15.97
- BRDG $36.21
- P/E Ratio
- RIGL $10.14
- BRDG N/A
- Revenue Growth
- RIGL 70.16
- BRDG 39.05
- 52 Week Low
- RIGL $7.48
- BRDG $6.81
- 52 Week High
- RIGL $29.82
- BRDG $11.69
- Technical
- Relative Strength Index (RSI)
- RIGL 61.71
- BRDG 44.24
- Support Level
- RIGL $18.63
- BRDG $8.98
- Resistance Level
- RIGL $20.99
- BRDG $9.37
- Average True Range (ATR)
- RIGL 1.07
- BRDG 0.21
- MACD
- RIGL 0.11
- BRDG -0.06
- Stochastic Oscillator
- RIGL 82.81
- BRDG 18.18
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.